Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer

BACKGROUND: Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD‐L1 and PD‐1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD‐L1 can predict the response rate to ch...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Nakamura, Yuki, Kobayashi, Tetsu, Nishii, Yoichi, Suzuki, Yuta, Saiki, Haruko, Ito, Kentaro, Watanabe, Fumiaki, Nishihama, Kota, Yasuma, Taro, D'Alessandro‐Gabazza, Corina N., Katsuta, Koji, Fujimoto, Hajime, Gabazza, Esteban C, Taguchi, Osamu, Hataji, Osamu
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6209791/
https://ncbi.nlm.nih.gov/pubmed/30209885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12861
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados